Methotrexate Biodim

Methotrexate, the active ingredient in Methotrexate Biodim, is an Antimetabolite presented as a sterile solution for intra‑arterial, intradiscal and intramuscular use. It is employed in the management of certain autoimmune disorders and selected cancers. GNH USA supplies Methotrexate Biodim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across several disease families, primarily as an antimetabolite that interferes with cell proliferation. Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: diminishes skin plaque formation and severity. Acute lymphoblastic leukemia: inhibits leukemic cell replication. Non‑Hodgkin lymphoma: impedes malignant lymphoid cell growth. Breast cancer: used in combination regimens to limit tumor cell division.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral ulcers or mucositis. - Elevated liver enzymes. - Mild bone marrow suppression (e.g., decreased white blood cells). - Skin rash or photosensitivity.

Serious or Rare Side Effects: - Severe bone marrow suppression leading to pancytopenia. - Hepatotoxicity or fibrosis with prolonged use. - Pulmonary toxicity, including interstitial pneumonitis. - Nephrotoxicity, especially with high doses. - Severe cutaneous adverse reactions (e.g., Stevens‑Johnson syndrome).

Methotrexate requires careful monitoring and patient education before and during therapy. - Baseline assessment: obtain liver function tests, renal function, and complete blood count prior to initiation. - Monitoring: repeat laboratory tests regularly to detect toxicity early. - Contraindications: avoid in patients with severe hepatic or renal impairment. - Pregnancy and lactation: discontinue and advise effective contraception; methotrexate is teratogenic. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors (e.g., omeprazole): may raise plasma levels. - Trimethoprim‑sulfamethoxazole: additive bone marrow suppression.

Moderate Interactions (Monitor Closely): - Penicillins (e.g., ampicillin): can reduce renal clearance. - Phenytoin: may lower methotrexate efficacy. - Live vaccines: risk of severe infection; avoid during therapy.